Latest Regulatory Filings News

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.

Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.

Vysarn Limited has reported a record first half for FY26 with revenue hitting $66.8 million and NPBT nearly doubling year-on-year to $10 million. The company reaffirms its full-year $20 million NPBT target, supported by strong industrial and advisory segment growth despite timing challenges in technology projects.

TZ Limited has amended its Appendix 4C for the December 2025 quarter, clarifying cash flow details and signalling improved operating cash flows ahead. The company also updates its funding arrangements, including loan repayments and a proposed trade finance facility.

Telix Pharmaceuticals has lodged a European marketing authorization application for TLX101-Px, a novel PET imaging agent targeting glioma brain cancer, aiming to enhance diagnostic precision and patient access across major European markets.

Klevo Rewards Ltd has responded to ASX concerns over a delayed director interest disclosure, attributing the lapse to administrative timing issues and pledging enhanced compliance measures.

BPH Energy Ltd reported a half-year net loss of $925,691, weighed down by investment write-downs and associate losses, while raising $1.2 million to fund exploration and development. The company’s future hinges on a Federal Court review of a critical offshore permit held by investee Advent Energy.

Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.

Kali Metals Limited has successfully raised approximately A$7 million through a Tranche 1 Placement, issuing over 38 million new shares at 18 cents each. This capital injection marks a significant step in the company’s funding strategy.